OPUS - A Cross-Over Study Of BCX4161 in the Prevention of HAE Attacks

• Research type

  Research Study

• Full title

  A Phase 2a double-blind placebo-controlled 2-period crossover study to evaluate the safety and efficacy of BCX4161 as a prophylactic treatment to reduce the frequency of attacks in subjects with hereditary angioedema

• IRAS ID

  135840

• Contact name

  Hilary Longhurst

• Contact email

  Hilary.Longhurst@bartshealth.nhs.uk

• Sponsor organisation

  BioCryst Pharmaceuticals Inc

• Eudract number

  2013-002319-82

• ISRCTN Number

  N/A

• REC name

  London - South East Research Ethics Committee

• REC reference

  13/LO/1881

• Date of REC Opinion

  3 Feb 2014

• REC opinion

  Further Information Favourable Opinion